Glow-in-the-Dark antibody could help surgeons spot prostate cancer

NCT ID NCT02048150

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tested a fluorescent antibody that attaches to prostate cancer cells. Seven men with moderate- to high-risk prostate cancer received the antibody before robotic prostate removal surgery. The goal was to see if the glowing antibody could help surgeons identify cancerous tissue during the operation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

anti-PSMA monoclonal antibody MDX1201-A488

What this could lead to

If it works, this could help surgeons see prostate cancer more clearly during surgery, potentially leading to more complete tumor removal.

What could go wrong

This is a very early, small trial with only 7 people, so results may not apply widely. The imaging technique may not improve outcomes or could miss some cancer cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States